Microbicide proves effective in reducing HIV infectionBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c3944 (Published 20 July 2010) Cite this as: BMJ 2010;341:c3944
- Bob Roehr
- 1Washington, DC
The quest to develop a topical vaginal product that protects against HIV infection took a huge step forward this week with news that results from a trial in South Africa showed that a new gel provided significant protection to the women who used it.
The randomised, double blind, placebo controlled trial used a gel containing the antiretroviral tenofovir and followed 889 women for an average of 18 months. It found that those who used the microbicide had an overall 39% lower rate of HIV infection than those in the placebo arm (5.6 versus 9.1 infections per 100 woman years (incidence rate ratio 0.61 (95% confidence interval 0.4 to 0.94; P=0.017)).
Importantly the researchers found a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial